Literature DB >> 31250550

Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.

Saman K Hashmi1, Jyotinder N Punia2, Andrea N Marcogliese2, Amos S Gaikwad2, Kevin E Fisher1,2, Angshumoy Roy2, Pulivarthi Rao2, Dolores H Lopez-Terrada2, Jo Ringrose2, Mignon L Loh3, Charlotte M Niemeyer4,5,6, Rachel E Rau1.   

Abstract

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. The hypomethylating agent, azacitidine, has been used as a bridging therapy to transplant. However, no patients have been treated with azacitidine without an HSCT post azacitidine. We report on an infant with JMML with somatic KRAS G12A mutation and monosomy 7 who achieved sustained remission following azacitidine monotherapy. He also developed an aberrant B-lymphoblast population which declined with similar kinetics as his JMML-associated abnormalities, suggesting that a B-lymphoblast population in JMML does not always progress to acute leukemia.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  B-lymphoblasts; JMML; azacitidine

Mesh：

Substances：

Year:  2019        PMID： 31250550      PMCID： PMC7328527          DOI： 10.1002/pbc.27905

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  19 in total

1.  Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.

Authors:  Annamaria Cseh; Charlotte M Niemeyer; Ayami Yoshimi; Michael Dworzak; Henrik Hasle; Marry M van den Heuvel-Eibrink; Franco Locatelli; Riccardo Masetti; Markus Schmugge; Ute Groß-Wieltsch; Andrea Candás; Andreas E Kulozik; Lale Olcay; Meinolf Suttorp; Ingrid Furlan; Brigitte Strahm; Christian Flotho
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS.

Authors:  Tomoo Osumi; Motohiro Kato; Meri Ouchi-Uchiyama; Daisuke Tomizawa; Keisuke Kataoka; Yoichi Fujii; Masafumi Seki; Junko Takita; Seishi Ogawa; Toru Uchiyama; Kentaro Ohki; Nobutaka Kiyokawa
Journal:  Pediatr Blood Cancer       Date:  2017-02-28       Impact factor: 3.167

Review 3.  How I treat juvenile myelomonocytic leukemia.

Authors:  Franco Locatelli; Charlotte M Niemeyer
Journal:  Blood       Date:  2015-01-06       Impact factor: 22.113

Review 4.  Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.

Authors:  Mignon L Loh
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

5.  Lymphoid blast crisis of B-lineage phenotype with monosomy 7 in a patient with juvenile chronic myelogenous leukemia (JCML).

Authors:  R C Lau; J Squire; L Brisson; S Kamel-Reid; T Grunberger; I Dubé; M Letarte; K Shannon; M H Freedman
Journal:  Leukemia       Date:  1994-05       Impact factor: 11.528

Review 6.  JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

Authors:  Katherine R Calvo; Susan Price; Raul C Braylan; Joao Bosco Oliveira; Michael Lenardo; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2015-02-17       Impact factor: 22.113

7.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

Authors:  Kazuyuki Matsuda; Akira Shimada; Nao Yoshida; Atsushi Ogawa; Akihiro Watanabe; Shuhei Yajima; Susumu Iizuka; Kazutoshi Koike; Fumio Yanai; Keiichiro Kawasaki; Masakatsu Yanagimachi; Akira Kikuchi; Yoshitoshi Ohtsuka; Eiko Hidaka; Kazuyoshi Yamauchi; Miyuki Tanaka; Ryu Yanagisawa; Yozo Nakazawa; Masaaki Shiohara; Atsushi Manabe; Seiji Kojima; Kenichi Koike
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

8.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

Authors:  Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

9.  Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Tali Mazor; Adam B Olshen; Huimin Geng; Laura C Gelston; Jon Akutagawa; Daniel B Lipka; Christoph Plass; Christian Flotho; Farid F Chehab; Benjamin S Braun; Joseph F Costello; Mignon L Loh
Journal:  Nat Commun       Date:  2017-12-19       Impact factor: 14.919

10.  The genomic landscape of juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330
View more
  3 in total

Review 1.  Treatment advances for pediatric and adult onset neoplasms with monocytosis.

Authors:  Kristen B McCullough; Alexis K Kuhn; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 2.  Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.

Authors:  Claudia Fiñana; Noel Gómez-Molina; Sandra Alonso-Moreno; Laura Belver
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

3.  Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.

Authors:  Charlotte M Niemeyer; Christian Flotho; Daniel B Lipka; Jan Starý; Claudia Rössig; André Baruchel; Thomas Klingebiel; Concetta Micalizzi; Gérard Michel; Karsten Nysom; Susana Rives; Markus Schmugge Liner; Marco Zecca; Maximilian Schönung; Irith Baumann; Peter Nöllke; Bouchra Benettaib; Noha Biserna; Jennifer Poon; Mathew Simcock; Meera Patturajan; Daniel Menezes; Allison Gaudy; Marry M van den Heuvel-Eibrink; Franco Locatelli
Journal:  Blood Adv       Date:  2021-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.